PE20121156A1 - Derivados de benzo[f]-1, 7-naftiridin-5-amina como moduladores de la actividad de tlr - Google Patents
Derivados de benzo[f]-1, 7-naftiridin-5-amina como moduladores de la actividad de tlrInfo
- Publication number
- PE20121156A1 PE20121156A1 PE2012000285A PE2012000285A PE20121156A1 PE 20121156 A1 PE20121156 A1 PE 20121156A1 PE 2012000285 A PE2012000285 A PE 2012000285A PE 2012000285 A PE2012000285 A PE 2012000285A PE 20121156 A1 PE20121156 A1 PE 20121156A1
- Authority
- PE
- Peru
- Prior art keywords
- naphthyridin
- benzo
- methyl
- modulators
- phosphone
- Prior art date
Links
- LQPYELMNUIINNN-UHFFFAOYSA-N benzo[f][1,7]naphthyridin-5-amine Chemical class C1=CN=C2C(N)=NC3=CC=CC=C3C2=C1 LQPYELMNUIINNN-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23921709P | 2009-09-02 | 2009-09-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20121156A1 true PE20121156A1 (es) | 2012-08-23 |
Family
ID=43625759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000285A PE20121156A1 (es) | 2009-09-02 | 2010-09-01 | Derivados de benzo[f]-1, 7-naftiridin-5-amina como moduladores de la actividad de tlr |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US9045470B2 (https=) |
| EP (1) | EP2473508B1 (https=) |
| JP (1) | JP5525614B2 (https=) |
| CN (1) | CN102712636B (https=) |
| AR (1) | AR078153A1 (https=) |
| AU (1) | AU2010308524B2 (https=) |
| BR (1) | BR112012004696B8 (https=) |
| CA (1) | CA2772657C (https=) |
| CL (1) | CL2012000535A1 (https=) |
| CY (1) | CY1119618T1 (https=) |
| DK (1) | DK2473508T3 (https=) |
| EA (1) | EA020962B1 (https=) |
| ES (1) | ES2627669T3 (https=) |
| HR (1) | HRP20170707T1 (https=) |
| HU (1) | HUE032323T2 (https=) |
| IN (1) | IN2012DN02736A (https=) |
| JO (1) | JO3257B1 (https=) |
| LT (1) | LT2473508T (https=) |
| MX (1) | MX2012002654A (https=) |
| PE (1) | PE20121156A1 (https=) |
| PL (1) | PL2473508T3 (https=) |
| PT (1) | PT2473508T (https=) |
| SI (1) | SI2473508T1 (https=) |
| SM (1) | SMT201700276T1 (https=) |
| TW (1) | TWI445708B (https=) |
| UY (1) | UY32874A (https=) |
| WO (1) | WO2011049677A1 (https=) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012125942A1 (en) * | 2011-03-16 | 2012-09-20 | University Of Medicine And Dentistry Of New Jersey | Combination therapy with leukotoxin |
| US8926990B2 (en) | 2009-10-13 | 2015-01-06 | Rutgers, The State University Of New Jersey | Treatment and diagnosis of inflammatory disorders and HIV |
| US10149889B2 (en) | 2005-11-25 | 2018-12-11 | Rutgers, The State University Of New Jersey | Compositions for the treatment of cancer, and methods for testing and using the same |
| RS53347B (sr) | 2008-12-09 | 2014-10-31 | Gilead Sciences, Inc. | Modulatori toll-sličnih receptora |
| WO2011027222A2 (en) | 2009-09-02 | 2011-03-10 | Novartis Ag | Immunogenic compositions including tlr activity modulators |
| BR112012014624A8 (pt) | 2009-12-15 | 2017-12-26 | Novartis Ag | suspensão homogênea de compostos de imunopotenciação e usos dos destes |
| EP2402028A1 (en) * | 2010-07-01 | 2012-01-04 | Sanofi Pasteur | Enterovirus vaccines for preventing and treating type 1 diabetes (II) |
| EP2591114B1 (en) | 2010-07-06 | 2016-06-08 | GlaxoSmithKline Biologicals SA | Immunisation of large mammals with low doses of rna |
| ES2557382T3 (es) | 2010-07-06 | 2016-01-25 | Glaxosmithkline Biologicals Sa | Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN |
| ES2646669T3 (es) | 2010-07-06 | 2017-12-14 | Glaxosmithkline Biologicals Sa | Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN |
| LT4226941T (lt) | 2010-08-31 | 2025-01-10 | Glaxosmithkline Biologicals Sa | Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui |
| AU2011295853A1 (en) * | 2010-09-01 | 2013-04-04 | Irm Llc | Adsorption of immunopotentiators to insoluble metal salts |
| WO2012051211A2 (en) | 2010-10-11 | 2012-04-19 | Novartis Ag | Antigen delivery platforms |
| WO2012117377A1 (en) | 2011-03-02 | 2012-09-07 | Novartis Ag | Combination vaccines with lower doses of antigen and/or adjuvant |
| US8900626B2 (en) * | 2011-06-20 | 2014-12-02 | Senju Usa, Inc. | Transdermal drug delivery system and method of using the same |
| EP2729165B1 (en) * | 2011-07-06 | 2017-11-08 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
| RU2014112343A (ru) * | 2011-09-01 | 2015-10-10 | Новартис Аг | Оставы антигенов staphylococcus aureus, содержащие адъюванты |
| FI123955B (en) * | 2011-11-25 | 2014-01-15 | Oncos Therapeutics Ltd | Oncolytic adenovirus |
| AU2013229465A1 (en) * | 2012-03-07 | 2014-09-04 | Novartis Ag | Adjuvanted formulations of rabies virus immunogens |
| JP2015510872A (ja) * | 2012-03-07 | 2015-04-13 | ノバルティス アーゲー | Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤 |
| SI2822947T1 (sl) * | 2012-03-07 | 2016-10-28 | Glaxosmithkline Biologicals S.A. | Argininske soli TLR7 agonista |
| MX372965B (es) * | 2012-03-08 | 2020-04-01 | Glaxosmithkline Biologicals Sa | Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo. |
| EP2674170B1 (en) | 2012-06-15 | 2014-11-19 | Invivogen | Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids |
| WO2014016152A1 (en) | 2012-07-27 | 2014-01-30 | Institut National De La Sante Et De La Recherche Medicale | Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia |
| US20150202277A1 (en) * | 2012-08-31 | 2015-07-23 | Novartis Ag | Stabilised proteins for immunising against staphylococcus aureus |
| EP2732825B1 (en) | 2012-11-19 | 2015-07-01 | Invivogen | Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist |
| CN103845731B (zh) * | 2012-12-05 | 2015-12-02 | 复旦大学 | 抗st2/il-1r4抗体在制备防治瘙痒药物中的应用 |
| CN109045294A (zh) * | 2013-01-10 | 2018-12-21 | 思齐乐 | 流感病毒免疫原性组合物及其应用 |
| BR112015018014A2 (pt) | 2013-02-01 | 2017-07-11 | Glaxosmithkline Biologicals Sa | liberação intradérmica de composições imunológicas compreendendo agonistas do receptor do tipo toll |
| EP2769738B1 (en) | 2013-02-22 | 2016-07-20 | Invivogen | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists |
| SG11201509265SA (en) | 2013-05-10 | 2015-12-30 | Novartis Ag | Avoiding narcolepsy risk in influenza vaccines |
| CN104338129B (zh) * | 2013-07-26 | 2017-05-24 | 中国科学院上海巴斯德研究所 | 雷帕霉素作为疫苗佐剂的用途及制备方法 |
| JP6522732B2 (ja) | 2014-07-11 | 2019-05-29 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖを治療するためのトール様受容体の調節因子 |
| SG11201701520TA (en) | 2014-09-16 | 2017-04-27 | Gilead Sciences Inc | Solid forms of a toll-like receptor modulator |
| EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
| US11779603B2 (en) | 2016-06-30 | 2023-10-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HERV-E reactive T cell receptors and methods of use |
| WO2018047888A1 (ja) * | 2016-09-09 | 2018-03-15 | 武田薬品工業株式会社 | 環状化合物 |
| AR111760A1 (es) * | 2017-05-19 | 2019-08-14 | Novartis Ag | Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral |
| MX2020005584A (es) | 2017-12-04 | 2020-09-14 | Intervet Int Bv | Vacunacion con particulas de replicon y adyuvante oleoso. |
| TW202003475A (zh) * | 2018-06-04 | 2020-01-16 | 美商亞博創新醫藥有限公司 | 含酸性基團之嘧啶化合物 |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
| WO2020162705A1 (ko) | 2019-02-08 | 2020-08-13 | 성균관대학교산학협력단 | 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도 |
| CN113490528B (zh) | 2019-02-15 | 2024-12-03 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| CA3123519A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CN113966326A (zh) * | 2019-04-05 | 2022-01-21 | 大日本住友制药株式会社 | 水溶性佐剂 |
| TWI810456B (zh) | 2019-05-22 | 2023-08-01 | 美商基利科學股份有限公司 | Tlr7調節化合物及hiv疫苗之組合 |
| CN114007737B (zh) * | 2019-07-03 | 2024-07-05 | 默克专利股份公司 | 抗体药物缀合物纯化 |
| CN114096560B (zh) | 2019-07-03 | 2025-06-13 | 默克专利股份公司 | 糖型纯化 |
| JP7829485B2 (ja) | 2019-12-20 | 2026-03-13 | ナミ セラピューティクス， インコーポレイテッド | がんの処置において有用なＴｏｌｌ様受容体（「ＴＬＲ」）アゴニストプロドラッグを含有する製剤化および／または共製剤化リポソーム組成物ならびにその方法 |
| BR112022011902A2 (pt) | 2019-12-20 | 2022-09-06 | Novartis Ag | Terapias de combinação |
| CA3170551A1 (en) | 2020-03-02 | 2021-09-10 | Yong Taik Lim | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
| KR20230027056A (ko) | 2020-06-23 | 2023-02-27 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 |
| WO2022009157A1 (en) | 2020-07-10 | 2022-01-13 | Novartis Ag | Lhc165 and spartalizumab combinations for treating solid tumors |
| JP7819176B2 (ja) | 2020-08-03 | 2026-02-24 | ノバルティス アーゲー | ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| US20230277525A1 (en) | 2020-08-04 | 2023-09-07 | Progeneer Inc | Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof |
| US20230346924A1 (en) | 2020-08-04 | 2023-11-02 | Progeneer Inc. | Mrna vaccine comprising adjuvant capable of kinetic control |
| JP7690221B2 (ja) | 2020-08-04 | 2025-06-10 | プロジェニア インコーポレイテッド | 動力学的に作用するアジュバントアンサンブル |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| JP2024545235A (ja) * | 2021-12-15 | 2024-12-05 | 上海翊石医薬科技有限公司 | 複素芳香族化合物、その製造方法及び使用 |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| AU2024302003A1 (en) * | 2023-06-15 | 2026-01-08 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Crystal form of enpp1 inhibitor |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2848965A1 (de) | 1978-11-11 | 1980-05-22 | Behringwerke Ag | Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine |
| US5389640A (en) * | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| IL117483A (en) | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
| US6180111B1 (en) | 1995-05-18 | 2001-01-30 | University Of Maryland | Vaccine delivery system |
| WO1997037026A1 (en) | 1996-04-02 | 1997-10-09 | Smithkline Beecham Corporation | Novel compounds |
| JP2000512487A (ja) | 1996-05-14 | 2000-09-26 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
| JP4469026B2 (ja) | 1996-10-31 | 2010-05-26 | ヒューマン ジノーム サイエンシーズ，インコーポレイテッド | Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅの抗原およびワクチン |
| GB9711964D0 (en) | 1997-06-09 | 1997-08-06 | Medical Res Council | Live attenuated vaccines |
| US6800744B1 (en) | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
| ES2301181T3 (es) | 1997-08-21 | 2008-06-16 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Mutantes nuevos de bacterias mucosas gram negativas y su aplicacion en vacunas. |
| JPH1180156A (ja) * | 1997-09-04 | 1999-03-26 | Hokuriku Seiyaku Co Ltd | １−（置換アリール）アルキル−１ｈ−イミダゾピリジン−４−アミン誘導体 |
| CA2671261A1 (en) | 1997-11-06 | 1999-05-20 | Novartis Vaccines And Diagnostics S.R.L. | Neisserial antigens |
| EP1034277B1 (en) | 1997-11-26 | 2012-06-27 | Inhibitex, Inc. | Extracellular matrix-binding proteins from Staphylococcus aureus |
| EP1047784B2 (en) | 1998-01-14 | 2015-03-18 | Novartis Vaccines and Diagnostics S.r.l. | Neissera meningitidis antigens |
| WO1999053940A1 (en) | 1998-04-23 | 1999-10-28 | Uab Research Foundation | PNEUMOCOCCAL SURFACE PROTEIN C(PspC), EPITOPIC REGIONS AND STRAIN SELECTION THEREOF, AND USES THEREFOR |
| EP2261338A3 (en) | 1998-05-01 | 2012-01-04 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
| GB9810193D0 (en) | 1998-05-12 | 1998-07-08 | Smithkline Beecham Biolog | Novel compounds |
| ATE361365T1 (de) | 1998-07-27 | 2007-05-15 | Sanofi Pasteur Ltd | Streptococcus pneumoniae proteine und nukleinsäuren |
| CN1318103A (zh) | 1998-07-27 | 2001-10-17 | 微生物技术有限公司 | 肺炎链球菌的核酸和蛋白质 |
| JP4714342B2 (ja) | 1998-08-31 | 2011-06-29 | ザ プラヴアスト フエロウス アンド スカラース オブ ザ カレツヂ オブ ザ ハリー アンド アンデイヴアイデツド トリニテイ オブ クイーン エリザベス ニヤー ダブリン | コアグラーゼ陰性スタフィロコカス菌に由来のポリペプチド及びポリヌクレオチド |
| ES2322409T3 (es) | 1998-08-31 | 2009-06-19 | Inhibitex, Inc. | Vacunas multicomponentes contra staphylococcus aureus. |
| BR9914374A (pt) | 1998-10-09 | 2002-09-17 | Chiron Corp | Sequências genÈmicas de neisseria e métodos para seu uso |
| GB9823978D0 (en) | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
| GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
| EP1140157B1 (en) | 1998-12-21 | 2009-02-18 | MedImmune, Inc. | Streptococcus pneumoniae proteins and immunogenic fragments for vaccines |
| CN1198932C (zh) | 1999-03-26 | 2005-04-27 | 科特克斯(Om)有限公司 | 肺炎链球菌抗原 |
| JP2003501110A (ja) | 1999-06-10 | 2003-01-14 | メディミューン，インコーポレーテッド | 肺炎連鎖球菌タンパク質とワクチン |
| EP1075841A1 (en) | 1999-08-13 | 2001-02-14 | Erasmus Universiteit Rotterdam | Pneumococcal vaccines |
| AU1917501A (en) | 1999-11-12 | 2001-06-06 | University Of Iowa Research Foundation, The | Control of neisserial membrane synthesis |
| PT2289545T (pt) | 2000-01-17 | 2016-09-06 | Glaxosmithkline Biologicals Sa | Vacina de omv suplementada contra meningococos |
| NZ521531A (en) | 2000-02-28 | 2005-12-23 | Chiron S | Heterologous expression of neisserial proteins |
| CA2404260A1 (en) | 2000-03-21 | 2001-09-27 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in prokaryotes |
| JP2003530872A (ja) | 2000-04-27 | 2003-10-21 | メディミューン，インコーポレイテッド | 免疫原肺炎連鎖球菌タンパク質とそのワクチン組成物 |
| NO20002828D0 (no) | 2000-06-02 | 2000-06-02 | Statens Inst For Folkehelse | Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav |
| US6495079B1 (en) | 2000-06-28 | 2002-12-17 | Prisma Fibers, Inc. | Process to prepare polymeric fibers with improved color and appearance |
| JP2004502415A (ja) | 2000-07-03 | 2004-01-29 | カイロン エセ．ピー．アー． | Ｃｈｌａｍｙｄｉａｐｎｅｕｍｏｎｉａｅに対する免疫化 |
| US20040091495A1 (en) | 2000-07-20 | 2004-05-13 | Lars Bjorck | Protein |
| ES2519440T3 (es) | 2000-07-27 | 2014-11-07 | Children's Hospital & Research Center At Oakland | Vacunas para la protección de amplio espectro contra enfermedades causadas por Neisseria meningitidis |
| GB0103170D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| AU8743001A (en) | 2000-08-28 | 2002-03-13 | Aventis Pasteur | Moraxella polypeptides and corresponding dna fragments and uses thereof |
| GB0022742D0 (en) | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
| CA2426738A1 (en) | 2000-10-26 | 2002-05-02 | David William Holden | Streptococcal genes |
| CA2881568C (en) | 2000-10-27 | 2019-09-24 | Novartis Vaccines And Diagnostics, Inc. | Nucleic acids and proteins from streptococcus groups a & b |
| AT410798B (de) | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
| GB0103171D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| GB0103424D0 (en) | 2001-02-12 | 2001-03-28 | Chiron Spa | Gonococcus proteins |
| AU2002306849A1 (en) | 2001-03-21 | 2002-10-08 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in microorganisms |
| GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| GB0108079D0 (en) | 2001-03-30 | 2001-05-23 | Microbial Technics Ltd | Protein |
| WO2002094851A2 (en) | 2001-05-18 | 2002-11-28 | The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Healthand Human Services, Centers For Disease Control And Prevention, Technology Transfer Office | Peptide vaccines against group a streptococci |
| MXPA03011701A (es) | 2001-06-15 | 2004-12-06 | Nhibitex Inc | Anticuerpos monoclonales y policlonales de reaccion que reconocen las proteinas de superficie a partir de estafilococos coagulasa-negativos y staphylococcus aureus. |
| GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
| ATE542829T1 (de) | 2001-08-02 | 2012-02-15 | Univ Sheffield | Impfstoff |
| RU2331435C2 (ru) | 2001-12-12 | 2008-08-20 | Чирон Срл. | Иммунизация против chlamydia trachomatis |
| GB0203403D0 (en) | 2002-02-13 | 2002-04-03 | Chiron Spa | Chlamydia cytotoxic-T cell epitopes |
| EP2275122A3 (en) | 2002-04-02 | 2011-05-18 | Ben Gurion University Of The Negev Research And Development Authority | Protein-based streptococcus pneumoniae vaccines |
| GB0210128D0 (en) | 2002-05-02 | 2002-06-12 | Chiron Spa | Nucleic acids and proteins from streptococcus groups A & B |
| KR20050010040A (ko) | 2002-06-11 | 2005-01-26 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 면역원성 조성물 |
| GB0213622D0 (en) | 2002-06-13 | 2002-07-24 | Glaxosmithkline Biolog Sa | Vaccine Corporation |
| US20060057160A1 (en) | 2002-08-02 | 2006-03-16 | Ralph Biemans | Vaccine composition |
| GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
| ES2504166T3 (es) | 2002-09-13 | 2014-10-08 | Novartis Vaccines And Diagnostics, Inc. | Vacuna de estreptococo del grupo B |
| HUE031886T2 (en) | 2002-10-11 | 2017-08-28 | Glaxosmithkline Biologicals Sa | Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| ES2529736T3 (es) | 2003-04-10 | 2015-02-25 | Novartis Vaccines And Diagnostics, Inc. | Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS |
| EP2311988A1 (en) | 2003-04-15 | 2011-04-20 | Intercell AG | S. pneumoniae antigens |
| DE10327439A1 (de) | 2003-06-18 | 2005-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| MXPA05013260A (es) | 2003-06-26 | 2006-03-09 | Chiron Corp | Composiciones inmunogenicas para chlamydia trachomatis. |
| GB0316560D0 (en) | 2003-07-15 | 2003-08-20 | Chiron Srl | Vesicle filtration |
| ES2505695T3 (es) | 2003-07-31 | 2014-10-10 | Novartis Vaccines And Diagnostics, Inc. | Composiciones inmunógenas para Streptococcus pyogenes |
| US20070134263A1 (en) | 2004-02-18 | 2007-06-14 | Anderson Annaliesa S | Polypeptides for inducing a protective immune response against staphyloococcus aureus |
| GB0419627D0 (en) | 2004-09-03 | 2004-10-06 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
| NZ553776A (en) | 2004-09-22 | 2010-05-28 | Glaxosmithkline Biolog Sa | Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide. |
| WO2006081259A2 (en) | 2005-01-27 | 2006-08-03 | Children's Hospital & Research Center At Oakland | Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
| US7442511B2 (en) | 2005-12-27 | 2008-10-28 | Obetech, Llc | Adipogenic adenoviruses as a biomarker for disease |
| AU2007281934B2 (en) | 2006-01-18 | 2012-11-15 | University Of Chicago | Compositions and methods related to Staphylococcal bacterium proteins |
| WO2007116322A2 (en) | 2006-02-17 | 2007-10-18 | Novartis Ag | Purification of bacterial antigens |
| ES2536426T3 (es) * | 2006-03-23 | 2015-05-25 | Novartis Ag | Compuestos de imidazoquinoxalina como inmunomoduladores |
| AR060187A1 (es) | 2006-03-30 | 2008-05-28 | Glaxosmithkline Biolog Sa | Composicion inmunogenica |
| EP2476433A1 (en) | 2006-03-30 | 2012-07-18 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| CN102015651B (zh) * | 2008-03-03 | 2014-12-31 | Irm责任有限公司 | 作为tlr活性调节剂的化合物和组合物 |
| JP5867952B2 (ja) * | 2009-06-10 | 2016-02-24 | ノバルティス アーゲー | ベンゾナフチリジン含有ワクチン |
| CN102760226B (zh) * | 2011-04-29 | 2015-07-01 | 贵州师范大学 | 一种基于实心正方形的试卷客观题答题卡定位方法 |
-
2010
- 2010-08-31 JO JOP/2010/0304A patent/JO3257B1/ar active
- 2010-08-31 TW TW099129346A patent/TWI445708B/zh active
- 2010-09-01 AU AU2010308524A patent/AU2010308524B2/en active Active
- 2010-09-01 PE PE2012000285A patent/PE20121156A1/es active IP Right Grant
- 2010-09-01 IN IN2736DEN2012 patent/IN2012DN02736A/en unknown
- 2010-09-01 EA EA201200406A patent/EA020962B1/ru not_active IP Right Cessation
- 2010-09-01 JP JP2012528021A patent/JP5525614B2/ja active Active
- 2010-09-01 EP EP10807754.6A patent/EP2473508B1/en active Active
- 2010-09-01 SM SM20170276T patent/SMT201700276T1/it unknown
- 2010-09-01 HU HUE10807754A patent/HUE032323T2/en unknown
- 2010-09-01 US US12/874,153 patent/US9045470B2/en active Active
- 2010-09-01 PT PT108077546T patent/PT2473508T/pt unknown
- 2010-09-01 WO PCT/US2010/047587 patent/WO2011049677A1/en not_active Ceased
- 2010-09-01 ES ES10807754.6T patent/ES2627669T3/es active Active
- 2010-09-01 PL PL10807754T patent/PL2473508T3/pl unknown
- 2010-09-01 MX MX2012002654A patent/MX2012002654A/es unknown
- 2010-09-01 BR BR112012004696A patent/BR112012004696B8/pt active IP Right Grant
- 2010-09-01 CN CN201080049422.8A patent/CN102712636B/zh active Active
- 2010-09-01 SI SI201031468A patent/SI2473508T1/sl unknown
- 2010-09-01 CA CA2772657A patent/CA2772657C/en active Active
- 2010-09-01 LT LTEP10807754.6T patent/LT2473508T/lt unknown
- 2010-09-01 HR HRP20170707TT patent/HRP20170707T1/hr unknown
- 2010-09-01 DK DK10807754.6T patent/DK2473508T3/en active
- 2010-09-02 AR ARP100103222A patent/AR078153A1/es active IP Right Grant
- 2010-09-02 UY UY0001032874A patent/UY32874A/es unknown
-
2012
- 2012-02-29 CL CL2012000535A patent/CL2012000535A1/es unknown
-
2015
- 2015-04-24 US US14/696,165 patent/US20150225432A1/en not_active Abandoned
-
2017
- 2017-06-08 CY CY20171100605T patent/CY1119618T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20121156A1 (es) | Derivados de benzo[f]-1, 7-naftiridin-5-amina como moduladores de la actividad de tlr | |
| PE20091621A1 (es) | Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen | |
| AR083873A1 (es) | Derivados de acido amino-fenil-pentanoico sustituidos como inhibidores de nep | |
| CO6160232A2 (es) | Derivados de bencimidazol | |
| ES2600636T3 (es) | Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2 | |
| PE20120992A1 (es) | Conjugados de dimeros de pirrolo[1,4] benzodiazepina como agentes anticancerosos | |
| AR082985A1 (es) | INHIBIDORES DE PI3K-d Y METODOS DE SU USO Y PREPARACION | |
| PE20121091A1 (es) | Derivados de purina o deazapurina utiles en el tratamiento de (inter alia) infecciones virales | |
| CO6341581A2 (es) | Derivados de heteroarilo como inhibidores de dgat1 | |
| PE20130382A1 (es) | Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a | |
| BR112013001335A2 (pt) | processo de preparo de derivados de amino-benzoil-benzofurano | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| CU23911B1 (es) | Derivados de amida espiro - ciclícas como moduladores de beta-2-adrenoreceptores útiles para el tratamiento de la bronquitis y el asma | |
| PE20091010A1 (es) | Derivados de tetrahidroquinolina | |
| PE20121182A1 (es) | Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina | |
| MX2015007883A (es) | Compuestos para protección de células. | |
| PE20090189A1 (es) | Derivados de aza-piridopirimidinona como agonistas de hm74a | |
| CO6230986A2 (es) | Compuesto de 4-piridinona y su uso para cancer | |
| PE20141940A1 (es) | Compuestos triciclicos, composiciones que los comprenden y usos de los mismos | |
| PE20090307A1 (es) | Derivados de 7-alquinil-1,8-naftiridonas como agentes inhibidores de vegfr-3 | |
| PE20120657A1 (es) | Compuesto para el tratamiento de trastornos metabolicos | |
| AR069607A1 (es) | Inhibidores de la estearoil-coa desaturasa | |
| AR074511A1 (es) | Proceso para la fabricacion de derivados del acido 5-metoximetilpiridin-2,3-dicarboxilico sustituido | |
| ES2606839T3 (es) | Tetraaza-ciclopenta[a]indenilo y su uso como moduladores alostéricos positivos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |